Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
MorphoSys AG MOR
$5.71
+$0.16 (2.88%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
753018640.00000000
-
week52high
6.15
-
week52low
3.17
-
Revenue
278267003
-
P/E TTM
-3
-
Beta
0.71374000
-
EPS
-1.18000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 04:00
Описание компании
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Overweight | 14 янв 2022 г. |
| Deutsche Bank | Hold | Buy | 06 авг 2021 г. |
| JP Morgan | Neutral | Overweight | 11 июн 2021 г. |
| SVB Leerink | Outperform | Market Perform | 03 июн 2021 г. |
| Bryan Garnier | Neutral | Buy | 03 июн 2021 г. |
| JMP Securities | Market Outperform | Market Outperform | 18 ноя 2022 г. |
| JP Morgan | Underweight | Neutral | 03 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
MorphoSys AG (MOR) Q1 2023 Earnings Call Transcript
Seeking Alpha
06 мая 2023 г. в 03:08
MorphoSys AG (NASDAQ:MOR ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Julia Neugebauer - Vice President, Head of Investor Relations Jean-Paul Kress - Chief Executive Officer Tim Demuth - Chief Research and Development Officer Joe Horvat - General Manager MorphoSys US Conference Call Participants Jason Butler - JMP Securities James Quigley - Morgan Stanley Zain Ebrahim - JPMorgan Vineet Agrawal - Citi Operator Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the First Quarter Interim Statement 2023 of MorphoSys.
Invitation to MorphoSys' First Quarter 2023 Financial Results Conference Call on May 4, 2023
Accesswire
27 апр 2023 г. в 16:20
Conference Call Alert MUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on May 4, 2023 at 02:00 pm CEST (01:00 pm BST; 08:00 am EDT) to present the results for the first quarter 2023 and provide an outlook for 2023.
MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study
Zacks Investment Research
06 апр 2023 г. в 13:42
As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.
Why Shares of MorphoSys Are Up Wednesday
The Motley Fool
05 апр 2023 г. в 14:34
MorphoSys had said it planned to cut preclinical programs and trim its workforce. The company said it expected top-line results for a myelofibrosis drug later this year.
MorphoSys AG (MOR) Q4 2022 Earnings Call Transcript
Seeking Alpha
16 мар 2023 г. в 11:10
MorphoSys AG (NASDAQ:MOR ) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET Company Participants Julia Neugebauer - Head of Investor Relations Jean-Paul Kress - Chief Executive Officer Tim Demuth - Chief Research and Development Officer Sung Lee - Chief Financial Officer Joe Horvat - General Manager MorphoSys US Conference Call Participants James Quigley - Morgan Stanley James Gordon - J.P. Morgan Rajan Sharma - Goldman Sachs Suzanne van Voorthuizen - Kempen & Co Mohamad Vaseghi - Frankfurt Main Research Julia Neugebauer Ladies and gentlemen, good afternoon and good morning.